Nanotechnology-based therapeutics for targeting inflammatory lung diseases

Area of Science:

• Pulmonary Medicine
• Nanotechnology
• Drug Delivery

Background:

• Inflammatory lung diseases like asthma, COPD, and pulmonary fibrosis often involve drugs with poor physiochemical properties, including low solubility, stability, and rapid clearance.
• These properties limit drug bioavailability and therapeutic index, hindering effective treatment.
• Current treatments face challenges in optimizing drug delivery and efficacy.

Purpose of the Study:

• To review current drug formulations and emerging therapeutic agents for inflammatory lung diseases.
• To explore the role and potential of nanotechnology in overcoming drug delivery challenges.
• To discuss future perspectives for nanotechnology-based treatments in pulmonary medicine.

Main Methods:

• Literature review of current research on drug properties and formulations for inflammatory lung diseases.
• Analysis of trends in drug development, including corticosteroids, long-acting β-agonists, and biomacromolecules (DNA, siRNA, mRNA).
• Examination of nanotechnology applications and their challenges in pulmonary drug delivery.

Main Results:

• Many drugs for inflammatory lung diseases suffer from poor solubility, stability, and rapid clearance, impacting bioavailability.
• Nanotechnology presents innovative strategies to enhance drug solubility, stability, and targeted delivery.
• Biomacromolecules like siRNA and mRNA are emerging as novel therapeutic options.

Conclusions:

• Optimizing drug physiochemical properties and delivery is crucial for treating inflammatory lung diseases.
• Nanotechnology holds significant potential to improve therapeutic outcomes by enhancing drug bioavailability and efficacy.
• Further research into nanotechnology applications is essential for advancing the treatment of asthma, COPD, and pulmonary fibrosis.